Employees: 01 (2023.0)Legal category: 5485Size: PMECreation date: 2023-08-04 (2 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINT-FORT-SUR-GIRONDE (17240), Charente-Maritime
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE BONNET-NORIGEON : revenue, balance sheet and financial ratios
PHARMACIE BONNET-NORIGEON is a French company
founded 2 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-FORT-SUR-GIRONDE (17240),
this company of category PME
shows in 2025 a net income positive of 92 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE BONNET-NORIGEON (SIREN 978370278)
Indicator
2025
2024
Revenue
N/C
N/C
Net income
91 728 €
74 899 €
EBITDA
N/C
N/C
Net margin
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE BONNET-NORIGEON generates positive net income of 92 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2024-2025: 75 k€ -> 92 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
91 728 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 230%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 25%. The balance between equity and debt is satisfactory.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
229.558%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
24.528%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2024
2025
Debt ratio
506.125
229.558
Financial autonomy
13.784
24.528
Repayment capacity
None
None
Cash flow / Revenue
None%
None%
Sector positioning
Debt ratio
229.562025
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Average
In 2025, the debt ratio of PHARMACIE BONNET-NORIGEON (229.56) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
24.53%2025
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Watch
In 2025, the financial autonomy of PHARMACIE BONNET-NORIGEON (24.5%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 204.59. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2024
2025
Liquidity ratio
202.192
204.588
Interest coverage
None
None
Sector positioning
Liquidity ratio
204.592025
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good
In 2025, the liquidity ratio of PHARMACIE BONNET-NORIGEON (204.59) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of PHARMACIE BONNET-NORIGEON in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE BONNET-NORIGEON is estimated at
1 457 110 €
(range 988 801€ - 2 286 406€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
988k€1457k€2286k€
1 457 110 €Range: 988 801€ - 2 286 406€
NAF 5 année 2025
Valuation method used
Net Income Multiple
91 728 €
×
15.9x
=1 457 110 €
Range: 988 802€ - 2 286 407€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE BONNET-NORIGEON with other companies in the same sector:
Frequently asked questions about PHARMACIE BONNET-NORIGEON
What is the revenue of PHARMACIE BONNET-NORIGEON ?
The revenue of PHARMACIE BONNET-NORIGEON is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE BONNET-NORIGEON profitable?
Yes, PHARMACIE BONNET-NORIGEON generated a net profit of 92 k€ in 2025.
Where is the headquarters of PHARMACIE BONNET-NORIGEON ?
The headquarters of PHARMACIE BONNET-NORIGEON is located in SAINT-FORT-SUR-GIRONDE (17240), in the department Charente-Maritime.
Where to find the tax return of PHARMACIE BONNET-NORIGEON ?
The tax return of PHARMACIE BONNET-NORIGEON is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE BONNET-NORIGEON operate?
PHARMACIE BONNET-NORIGEON operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart